Compare DexCom, Inc. (DXCM) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Quantum Computing Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Quantum Computing Inc trades at $7.46 (market cap $1.69B). The key difference: DexCom, Inc. is far larger — about 18.9× Quantum Computing Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Quantum Computing Inc for 25 Days on average.
| DXCM | QUBT | |
|---|---|---|
Market Cap | $31.86B | $1.69B |
Volume | 3,607,070 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $92.34 | $21.78 |
52-Week Low | $54.84 | $6.31 |
Typical Hold Time | 62 Days | 25 Days |
Enterprise Value | $31.32B | $753.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Quantum Computing Inc. (QUBT) trades at $7.44, down 2.36% on the day, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and shareholder litigation pose challenges.
QUBT offers significant upside potential with a consensus price target of $17.33 (133% upside) and 75% analyst buy ratings, supported by strong revenue growth and technological advancements. However, the stock carries high risk due to persistent losses, negative cash flow from operations, and execution challenges in the competitive quantum computing space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
